For research use only. Not for therapeutic Use.
Briquilimab (Cat No.:I042149) is a monoclonal antibody developed by AbbVie, targeting the PD-1 (Programmed cell death protein 1) pathway. It works by inhibiting PD-1, a receptor on immune cells, allowing the immune system to better recognize and attack cancer cells. Briquilimab is being investigated in clinical trials for various cancers, including non-small cell lung cancer and melanoma. By blocking the interaction between PD-1 and its ligands, it aims to enhance anti-tumor immunity and improve treatment outcomes for patients with advanced or resistant cancers.
| Catalog Number | I042149 |
| CAS Number | 2574591-89-0 |
| Purity | ≥95% |
